Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX(® )recurrence score <26

The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A previously published algorithmic model gave recommendations for which cases to send out for Oncotype DX(®) (ODX) testing. This study is a multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Bradley M., Gimenez‐Sanders, Mary Ann, Soukiazian, Armen, Breaux, Andrea C., Skinner, Kristin, Shayne, Michelle, Soukiazian, Nyrie, Ling, Marilyn, Hicks, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675710/
https://www.ncbi.nlm.nih.gov/pubmed/31199586
http://dx.doi.org/10.1002/cam4.2323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675710/
https://www.ncbi.nlm.nih.gov/pubmed/31199586
http://dx.doi.org/10.1002/cam4.2323

Ejemplares similares